57
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access
      Gut
      BMJ Publishing Group
      gastroesophageal reflux disease, ph monitoring, manometry, endoscopy

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Clinical history, questionnaire data and response to antisecretory therapy are insufficient to make a conclusive diagnosis of GERD in isolation, but are of value in determining need for further investigation. Conclusive evidence for reflux on oesophageal testing include advanced grade erosive oesophagitis (LA grades C and D), long-segment Barrett’s mucosa or peptic strictures on endoscopy or distal oesophageal acid exposure time (AET) >6% on ambulatory pH or pH-impedance monitoring. A normal endoscopy does not exclude GERD, but provides supportive evidence refuting GERD in conjunction with distal AET <4% and <40 reflux episodes on pH-impedance monitoring off proton pump inhibitors. Reflux-symptom association on ambulatory reflux monitoring provides supportive evidence for reflux triggered symptoms, and may predict a better treatment outcome when present. When endoscopy and pH or pH-impedance monitoring are inconclusive, adjunctive evidence from biopsy findings (histopathology scores, dilated intercellular spaces), motor evaluation (hypotensive lower oesophageal sphincter, hiatus hernia and oesophageal body hypomotility on high-resolution manometry) and novel impedance metrics (baseline impedance, postreflux swallow-induced peristaltic wave index) can add confidence for a GERD diagnosis; however, diagnosis cannot be based on these findings alone. An assessment of anatomy, motor function, reflux burden and symptomatic phenotype will therefore help direct management. Future GERD management strategies should focus on defining individual patient phenotypes based on the level of refluxate exposure, mechanism of reflux, efficacy of clearance, underlying anatomy of the oesophagogastric junction and psychometrics defining symptomatic presentations.

          Related collections

          Most cited references115

          • Record: found
          • Abstract: found
          • Article: not found

          Management of Gastroesophageal Reflux Disease.

          Management of gastroesophageal reflux disease (GERD) commonly starts with an empiric trial of proton pump inhibitor (PPI) therapy and complementary lifestyle measures, for patients without alarm symptoms. Optimization of therapy (improving compliance and timing of PPI doses), or increasing PPI dosage to twice daily in select circumstances, can reduce persistent symptoms. Patients with continued symptoms can be evaluated with endoscopy and tests of esophageal physiology, to better determine their disease phenotype and optimize treatment. Laparoscopic fundoplication, magnetic sphincter augmentation, and endoscopic therapies can benefit patients with well-characterized GERD. Patients with functional diseases that overlap with or mimic GERD can also be treated with neuromodulators (primarily antidepressants), or psychological interventions (psychotherapy, hypnotherapy, cognitive and behavioral therapy). Future approaches to treatment of GERD include potassium-competitive acid blockers, reflux-reducing agents, bile acid binders, injection of inert substances into the esophagogastric junction, and electrical stimulation of the lower esophageal sphincter.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Accuracy of the diagnosis of GORD by questionnaire, physicians and a trial of proton pump inhibitor treatment: the Diamond Study.

            The aim of this study was to determine the accuracy of the diagnosis of gastro-oesophageal reflux disease (GORD) by the Reflux Disease Questionnaire (RDQ), family practitioners, gastroenterologists and a test of esomeprazole therapy. This was a single-blind, single-arm study over 3-4 weeks from September 2005 to November 2006. Each symptom-based diagnostic assessment was made blinded to prior diagnoses. Patients were those presenting to their family practitioner with troublesome upper gastrointestinal symptoms (n=308). The RDQ was completed and a symptom-based diagnosis was made by the family practitioner. Placebo esomeprazole was started. Gastroenterologists made a symptom-based diagnosis and then performed endoscopy with 48 h oesophageal pH and symptom association monitoring to determine the presence/absence of GORD. Symptoms were recorded during treatment with 40 mg of esomeprazole for 2 weeks. The main outcome measure was RDQ scoring for the presence of GORD compared with symptom-based diagnosis by family physicians and gastroenterologists. GORD was present in 203/308 (66%) patients. Only 49% of the patients with GORD selected either heartburn or regurgitation as the most troublesome symptom. Sensitivity and specificity, respectively, of the symptom-based diagnosis of GORD, were 62% and 67% for the RDQ, 63% and 63% for family practitioners, and 67% and 70% for gastroenterologists. Symptom response to esomeprazole was neither sensitive nor specific for the diagnosis of GORD. The RDQ, family practitioners and gastroenterologists have moderate and similar accuracy for diagnosis of GORD. Symptom response to a 2 week course of 40 mg of esomeprazole does not add diagnostic precision.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Screening for Barrett's esophagus in colonoscopy patients with and without heartburn.

              The population prevalence of Barrett's esophagus (BE) is uncertain. Our aim was to describe the prevalence of BE in a volunteer population. Upper endoscopy (EGD) was performed in 961 persons with no prior history of EGD who were scheduled for colonoscopy. Symptom questionnaires were completed prior to endoscopy. Biopsy specimens were taken from the gastric cardia and any columnar mucosa extending > or =5 mm into the tubular esophagus and from the stomach for H. pylori infection in the last 812 patients. The study sample was biased toward persons undergoing colonoscopy, males, and persons with upper GI symptoms. The prevalence of BE was 65 of 961 (6.8%) patients, including 12 (1.2%) with long-segment BE (LSBE). Among 556 subjects who had never had heartburn, the prevalences of BE and LSBE were 5.6% and 0.36%, respectively. Among 384 subjects with a history of any heartburn, the prevalences of BE and LSBE were 8.3% and 2.6%, respectively. In a univariate analysis, LSBE was more common in those with any heartburn vs. those with no heartburn (P = 0.01), but the sample size was insufficient to allow multivariate analysis of predictors of LSBE. In a multivariate analysis, BE was associated with increasing age (P = 0.02), white race (P = 0.03), and negative H. pylori status (P = 0.04). Overall, BE was not associated with heartburn, although heartburn was more common in persons with LSBE or circumferential short segments. LSBE is very uncommon in patients who have no history of heartburn. SSBE is relatively common in persons age > or =40 years with no prior endoscopy, irrespective of heartburn history.
                Bookmark

                Author and article information

                Journal
                Gut
                Gut
                gutjnl
                gut
                Gut
                BMJ Publishing Group (BMA House, Tavistock Square, London, WC1H 9JR )
                0017-5749
                1468-3288
                July 2018
                3 February 2018
                : 67
                : 7
                : 1351-1362
                Affiliations
                [1 ] departmentDivision of Gastroenterology , Washington University School of Medicine , St Louis, Missouri, USA
                [2 ] departmentDivision of Gastroenterology, Department of Medicine , Northwestern University , Chicago, Illinois, USA
                [3 ] departmentDivision of Gastroenterology, Department of Surgical, Oncological and Gastroenterological Sciences , University of Padua , Padua, Italy
                [4 ] departmentDepartment of Gastroenterology , Bordeaux University Hospital, Université de Bordeaux , Bordeaux, France
                [5 ] departmentDigestive Physiology , Hopital E Herriot, Hospices Civils de Lyon, Université de Lyon , Lyon, France
                [6 ] departmentDigestive Physiology , Université de Lyon, Lyon I University , Lyon, France
                [7 ] Université de Lyon, Inserm U1032 , Lyon, France
                [8 ] departmentDepartment of Gastroenterology and Hepatology , Academic Medical Center , Amsterdam, The Netherlands
                [9 ] departmentDivision of Gastroenterology , Vanderbilt University Medical Center , Nashville, Tennessee, USA
                [10 ] Barts and The London School of Medicine and Dentistry, Queen Mary University of London , London, UK
                [11 ] departmentGastroenterology , St. Claraspital, Kleinriehenstrasse 30 , Basel, Switzerland
                [12 ] Zürich Neurogastroenterology and Motility Research Group, Clinic for Gastroenterology and Hepatology, University Hospital of Zürich , Zürich, Switzerland
                [13 ] departmentDivision of Gastroenterology and Hepatology , Mayo Clinic , Scottsdale, Arizona, USA
                [14 ] departmentDivision of Gastroenterology , University Clinics for Visceral Surgery and Medicine, Bern University Hospital , Bern, Switzerland
                [15 ] departmentDepartment of Gastroenterology , Catholic University of Leuven , Leuven, Belgium
                Author notes
                [Correspondence to ] Professor C Prakash Gyawali, Division of Gastroenterology, Washington University School of Medicine, St. Louis, MO 63110, USA; cprakash@ 123456wustl.edu
                Author information
                http://orcid.org/0000-0003-4394-5584
                Article
                gutjnl-2017-314722
                10.1136/gutjnl-2017-314722
                6031267
                29437910
                fb17a154-d0c4-4ce5-8c17-40d89c7fec65
                © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

                This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

                History
                : 26 December 2017
                : 11 January 2018
                : 14 January 2018
                Categories
                Recent Advances in Clinical Practice
                1506
                1240
                2312
                Custom metadata
                unlocked

                Gastroenterology & Hepatology
                gastroesophageal reflux disease,ph monitoring,manometry,endoscopy

                Comments

                Comment on this article

                scite_

                Similar content77

                Cited by304

                Most referenced authors1,567